Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 1 32Phase 1/2 26Phase 3 6Phase NA 5Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Leukemia, Myeloid, Acute 2Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Older Patients 1Myasthenia Gravis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 11Cytarabine 8Methotrexate 6Etoposide 6Dexamethasone 6Vincristine 5Radiotherapy 5Doxorubicin 5Daunorubicin 5pegaspargase 4Trimethoprim, Sulfamethoxazole Drug Combination 4Mercaptopurine 4Idarubicin 4gamma-Globulins 3fludarabine phosphate 3Whole-Body Irradiation 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methylprednisolone 3Gemtuzumab 3Filgrastim 3Clofarabine 3Ciprofloxacin 3Busulfan 3etoposide phosphate 2blinatumomab 2Thioguanine 2Melphalan 2Karyotyping 2Injections, Spinal 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia × fludarabine × Clear all
NCT07157514 2025-09-10

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Actinium Pharmaceuticals

Phase 2/3 Not yet recruiting
306 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡